Search Results
MC# 22-21
A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies
MC# 22-27
A Phase I, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
MC# 21-10
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as a Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
MC# 22-01
A Phase I, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants with Advanced Solid Tumors
MC# 22-19
Phase I/II Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
MC# 22-26
A Phase I/II Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose
MC# 23-04
A Phase I Study of ASP1002 in Participants with Metastatic or Locally Advanced Solid Tumors
MC# 22-10
A Phase I First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants with Advanced Malignant Tumors
MC# 22-42
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase I Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
